Showing results (581-590 of 755) with videos related to

Sort By:
Pageof 76
Nature Communications|June 6, 2019
Emergent bound states and impurity pairs in chemically doped Shastry-Sutherland systemZhenzhong Shi, William Steinhardt, David Graf, et al.
RSC Advances|May 9, 2022
Photon upconversion for the enhancement of microfluidic photochemical synthesisM Wu, B A Moser, T M Steeves, et al.
Therapeutic Advances in Hematology|March 5, 2026
Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasmsXiang Zhou, Julia Mersi, Christine Riedhammer, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2021
A physical model of mantis shrimp for exploring the dynamics of ultrafast systemsEmma Steinhardt, Nak-Seung P Hyun, Je-Sung Koh, et al.
Journal of Behavioral Medicine|July 5, 2001
Differences in functional immune responses of high vs. low hardy healthy individualsC L Dolbier, R R Cocke, J A Leiferman, et al.
Nature Communications|April 28, 2022
Discovery of quantum phases in the Shastry-Sutherland compound SrCu2(BO3)2 under extreme conditions of field and pressureZhenzhong Shi, Sachith Dissanayake, Philippe Corboz, et al.
Plos One|October 29, 2019
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencingVidya Balagopal, Andrew Hantel, Sabah Kadri, et al.
Gastroenterology|October 1, 1991
Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IVH Lochs, H J Steinhardt, B Klaus-Wentz, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 1, 1989
Long-term function of human cardiac allografts assessed by two-dimensional echocardiographyM L Antunes, H M Spotnitz, M B Clark, et al.
Cancer Medicine|July 2, 2020
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myelomaXiang Zhou, Maximilian J Steinhardt, Denise Grathwohl, et al.
Pageof 76